AACR 2022 | Update on the INO-VATE trial: inotuzumab vs chemotherapy for ALL
Yaqi Zhao, MSc, St. Jude Children’s Research Hospital, Memphis, TN, outlines some findings from the INO-VATE trial (NCT01564784). This Phase III trial assessed how patients with acute lymphoblastic leukemia (ALL) with different leukemic subtypes and genomic alterations responded to inotuzumab compared to standard-of-care chemotherapy. The trial consisted of 326 patients, with approximately half of the patients receiving inotuzumab. Bone marrow samples collected from the patients before treatment underwent RNA sequencing with analysis of gene expression profiles. The trial demonstrated the benefits of inotuzumab for patients with ALL across all leukemic subtypes and genomic alterations. Importantly, patients with the high-risk (Ph)-like subtype and TP53 alteration had a significantly higher complete remission rate. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.
